治疗视网膜黄斑病变的双特异性抗体:faricimab  

A bispecific antibody for treating retinal macular degeneration:faricimab

作　　者：周瑾 杨晓姣 赵振宇[1] ZHOU Jin;YANG Xiao-jiao;ZHAO Zhen-yu(NHC Key Laboratory of Hormones and Development,Tianjin Key Laboratory of Metabolic Diseases,Chu Hsien-l Memorial Hospital/Tianjin Institute of Endocrinology,Tianjin Medical University,TIANJIN 300134,China)

机构地区：[1]天津医科大学朱宪彝纪念医院/天津市内分泌研究所、国家卫健委激素与发育重点实验室、天津市代谢性疾病重点实验室,天津300134

出　　处：《中国新药与临床杂志》2023年第7期436-438,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：faricimab是一种能同时与血管内皮生长因子A和血管生成素2结合的双特异性抗体,由基因泰克公司开发,于2022年1月获美国食品和药物管理局审批通过用于湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的治疗。目前临床研究表明,与现有的抗血管内皮生长因子治疗药物雷珠单抗、阿柏西普相比,faricimab可通过更少的注射频率达到相当的治疗效果,从而降低患者治疗负担,提高其依从性。faricimab最常见的不良反应为结膜出血。faricimab is a bispecific antibody that binds to both vascular endothelial growth factor A and angiopoietin 2.It was developed by Genentech and approved by the U.S.Food and Drug Administration in the treatment of wet age-related macular degeneration and diabetic macular edema in January 2022.At present,clinical studies have shown that faricimab can achieve a comparable therapeutic effect with fewer frequent injections than existing anti-vascular endothelial growth factor therapies drugs,such as ranibizumab and aflibercept,thereby reducing the burden of treatment and improving patient compliance.The most common adverse reaction of faricimab is conjunctival bleeding.

关 键 词：faricimab 抗体 双特异性 黄斑变性 

分 类 号：R774.5[医药卫生—眼科] R988.1[医药卫生—临床医学]